All In Biotech

NDA 020857 · Viiv Hlthcare

Combivir

Lamivudine, Zidovudine · Oral · Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Priority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: May 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Sep 26, 1997

Approved uses

2

Original approval plus efficacy supplements

Registered trials

737

226 Phase 3, 25 recruiting

FAERS reports

7,705

6,925 serious, 595 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, and EXACERBATIONS OF HEPATITIS B Zidovudine, a component of COMBIVIR (lamivudine and zidovudine) tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV ‑ 1) disease [see Warnings and Precautions ( 5.1 )] . Prolonged use of zidovudine has been associated with symptomatic myopathy [see Warnings and Precautions ( 5.2 )] . Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including lamivudine and zidovudine (components of COMBIVIR). Discontinue COMBIVIR if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur [see Warnings and Precautions ( 5.3 )] . Severe...

What it is approved for

From the label in effect Aug 22, 2023.

COMBIVIR, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. COMBIVIR, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. ( 1 )

Mechanism: COMBIVIR is an antiretroviral agent [see Microbiology ( 12.4 )] .

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 2, 2009 Supplement 23 · Efficacy · priority review LetterLabel
  • Sep 26, 1997 Original approval · Type 4 - New Combination · priority review
1 products under this application
  • COMBIVIR · LAMIVUDINE 150MG; ZIDOVUDINE 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lamivudine" as an intervention, any sponsor and status, largest first.

All 737 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug exposure during pregnancy1,147
  • foetal exposure during pregnancy720
  • pain601
  • anxiety568
  • emotional distress557
  • anhedonia504
  • anaemia453
  • abortion spontaneous443
  • maternal exposure during pregnancy381
  • premature baby363
  • chronic kidney disease327
  • pyrexia285

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004503
2005614
2006564
2007506
2008479
2009522
2010664
2011373
2012401
2013298
2014332
2015469
2016245
2017179
2018266
2019332
2020339
2021277
2022184
202352
202449
202521
202618

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Combivir (Lamivudine/Zidovudine)

2024 spending

$42K

Beneficiaries

15

36 claims

Per beneficiary

$2,784

$15.13 per unit

View as table
YearSpending
2020$361,109
2021$257,752
2022$231,984
2023$167,802
2024$41,767

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,048 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.